ASCO 2014 – Immuno-Oncology

Phase 2 Trial of Nivolumab and VEGF Inhibitors in First-Line Metastatic Renal Cell Carcinoma

ASCO 2014 – Immuno-Oncology

MPDL3280A, an Anti-PD-L1 Monoclonal Antibody, in Metastatic Bladder Cancer

ASCO 2014 – Immuno-Oncology

Pharmacokinetics of MEDI4736, an Anti-PD-L1 Monoclonal Antibody, in Advanced Solid Tumors

ASCO 2014 – Immuno-Oncology

Immuno-Oncology: The New Frontier?

ASCO 2014 – Immuno-Oncology

Ipilimumab Combined with Cytotoxic Chemotherapy in Metastatic Melanoma

ASCO 2014 – Immuno-Oncology

Doublets and Triple Combinations in Metastatic Melanoma

ASCO 2014 – Immuno-Oncology

Stereotactic Radiosurgery and Ipilimumab for Melanoma Brain Metastases

ASCO 2014 – Immuno-Oncology

Peginterferon alfa-2b Combined with Ipilimumab for Advanced Melanoma

ASCO 2014 – Immuno-Oncology

Single-Agent Nivolumab in Advanced NSCLC

ASCO 2014 – Immuno-Oncology

Nivolumab Combined with Platinum-Based Doublet Chemotherapy in Advanced NSCLC

ASCO 2014 – Immuno-Oncology

Page 1 of 3

1
2
3